Geron Corporation announced that its management team will present at the Bank of America Securities 2026 Healthcare Conference on May 12 and the Stifel Virtual Targeted Oncology Forum on May 20. These presentations will provide updates on Geron's commercial-stage biopharmaceutical developments, including its approved telomerase inhibitor RYTELO® for certain blood cancers and ongoing Phase 3 trials. Investors can access live and archived webcasts on Geron's website. This engagement highlights Geron's efforts to advance treatments for blood cancer and keep investors informed on progress and clinical developments.
Equinor ASA will begin the third tranche of its 2026 share buy-back program on July 23, 2026, with purchases up to USD 371.3 million, contributing to a total tranche value of USD 1.125 billion including shares redeemed from the Norwegian State. This ...
Equinor ASA announced a cash dividend of $0.39 per share for the second quarter of 2026. The important dates include the last day inclusive on November 12, 2026, ex-dividend dates on November 13 (Oslo) and November 16 (NYSE), with the record date als...
Equinor ASA will begin the third tranche of its 2026 share buyback program on July 23, 2026, with a budget of up to $1.125 billion. This tranche includes $371.3 million worth of shares to be bought from the market and will conclude by October 26, 202...
Enigmatig Limited has invested in 'KUNGFULAND,' the first scripted feature-length action-comedy co-produced by Singapore and Canada using virtual production technology. The film, shot in Singapore, pays homage to 1970s Hong Kong martial arts cinema a...
Enigmatig Limited has invested in KUNGFULAND, the first scripted feature-length action-comedy co-produced by Singapore and Canada using virtual production technology. Filming began in June 2026 in Singapore, blending advanced LED wall technology with...
